[CH3:1][N:2]([C:12]1[CH:17]=[CH:16][N:15]=[CH:14][CH:13]=1)[CH2:3][CH2:4][N:5]1[CH2:10][CH2:9][NH:8][CH2:7][C:6]1=[O:11].[Cl:18][C:19]1[CH:20]=[CH:21][C:22]2[CH:26]=[C:25]([S:27](Cl)(=[O:29])=[O:28])[S:24][C:23]=2[CH:31]=1>>[Cl:18][C:19]1[CH:20]=[CH:21][C:22]2[CH:26]=[C:25]([S:27]([N:8]3[CH2:9][CH2:10][N:5]([CH2:4][CH2:3][N:2]([CH3:1])[C:12]4[CH:13]=[CH:14][N:15]=[CH:16][CH:17]=4)[C:6](=[O:11])[CH2:7]3)(=[O:29])=[O:28])[S:24][C:23]=2[CH:31]=1A portion (˜50%) of the crude 1-[2-{(Methyl)-(pyridin-4-yl)-amino}-ethyl]-piperazin-2-one, EXAMPLE 93 is reacted with 6-chloro-benzo[b]thiophene-2-sulfonyl chloride (54 mg, 0.20 mmol), EXAMPLE 1, using same procedure as described in EXAMPLE 719. The residue obtained after HPLC purification is subjected to silica gel chromatography using NH4OH/MeOH/CH2Cl2 (1:4:95) as eluant to give title compound (30 mg, 0.064 mmol) as a white solid. MS m/z 465, 457 (M+1); 1H NMR (CDCl3, 300 MHz) δ8.15 (d, 2H), 7.88 (s, 1H), 7.85 (d, 1H), 7.79 (s, 1H), 7.47 (d, 1H), 6.47 (d. 2H), 3.80 (s, 2H), 3.50 (m, 4H), 3.43 (d, 2H), 3.30 (d, 2H), 2.98 (s, 3H).